SHORT MINI-FUTURE - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 01:46:36 2024-05-28 pm EDT | ||
| 3.03 EUR | +5.21% |
|
| Current month | -4.72% | ||
| 1 month | -9.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 3.03 | +5.21% |
| 24-05-27 | 2.88 | +5.88% |
| 24-05-24 | 2.72 | +1.87% |
| 24-05-23 | 2.67 | -8.25% |
| 24-05-22 | 2.91 | +2.46% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 01:46 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAK |
| ISIN | DE000VD1XAK8 |
| Date issued | 2024-03-08 |
| Strike | 1,143 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.07 € |
|---|---|
| Lowest since issue | 2.67 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
